Abbott has declared a quarterly common dividend of 63 cents per share, marking the 410th consecutive quarterly dividend paid by the company since 1924. The board of directors approved the payout, continuing a streak of shareholder returns that spans over a century. The cash dividend is payable on Aug. 17, 2026, to shareholders of record at the close of business on July 15, 2026.

The company has increased its dividend payout for 54 consecutive years. This track record qualifies Abbott as a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.

Dividend Details

The dividend of 63 cents per share applies to common stockholders. Abbott operates as a global healthcare leader, with a portfolio spanning diagnostics, medical devices, nutritionals, and branded generic medicines. The company serves people in more than 160 countries.

Abbott India Limited has announced the appointment of Ms. Swati Pathak as the Associate Director - Operations. The appointment is effective June 1, 2026, and was approved by the company's Board of Directors based on the recommendation of the Nomination and Remuneration Committee. Ms. Pathak will serve as part of the Senior Management team of abbott .

Ms. Pathak possesses over 22 years of professional experience. Most recently, she led the New Product Introduction (NPI) & Therapy Area Strategy (TAS) function for Abbott's Specialty Care business in India. In this capacity, she established NPI as a key growth engine, ensuring the timely launch of multiple products across various therapy areas. Her efforts included lifecycle management initiatives and the development of a robust pipeline to support sustained growth.

She joined Abbott in 2007 as a Research Scientist in Innovation and Development (I&D). She subsequently transitioned into Project Management in 2010 and later served in Portfolio Strategy roles until 2022. Throughout her tenure, she has been a key contributor to Abbott's I&D transformation, acting as a strategic partner to drive incremental growth and deliver critical revenue through strong project execution. Additionally, she played a pivotal role in establishing and institutionalizing Project Management Office (PMO) processes within I&D and led several major NPI launches across Abbott's pharmaceutical business in India.

Prior to her tenure at Abbott, Ms. Pathak worked with Ipca R&D for four years as a formulation development scientist focusing on the US and EU markets. She holds a Bachelor's degree in Pharmacy from Pune University and a postgraduate qualification in Bioinformatics and Patent Law from NALSAR, Hyderabad. Her contributions to innovation and delivery excellence have been recognized with multiple prestigious awards, including the VP Award, Da Vinci Award, and MD Awards.

The company confirmed that Ms. Swati Pathak is not related to any of the Directors, Key Managerial Personnel, or Senior Management of the Company. The appointment was communicated to the stock exchanges in compliance with Regulation 30 of the SEBI Listing Regulations.

Appointment Details